© 2023 BioMarin. All rights reserved.

Jonathan Day, MBBS, Ph.D., FFPM, FESC, MRCS, joined BioMarin in August 2017 and currently serves as Vice President, Medical Director, Clinical Science, where he leads the Global Clinical Sciences team. From 2017 to March 2020, he served as Executive Medical Director, Clinical Science, leading clinical development of our investigational therapy for achondroplasia.

Dr. Day previously worked as Medical Director for AstraZeneca in the U.K. and Ireland. Prior to this role, he held a variety of positions at The Medicines Company, where he designed and initiated the EUROMAX study, led the regulatory filings for bivalirudin (Angiox), advanced the serene protease inhibitor MDCO-2010 through early development, and led the clinical program for cangrelor (Kengreal) from Phase 3 through approval in the U.S. and Europe. Dr. Day also worked at Nycomed (now part of Takeda) and spent ten years in the U.K. National Health Service, specializing in cardiothoracic surgery.

Dr. Day earned an MBBS degree from St. Bartholomew’s and Royal London Hospital Medical School and MRCS in surgery from the Royal College of Surgeons of England. He also earned a Ph.D. in thrombin inhibition from Imperial College London. Dr. Day is a Fellow of the European Society of Cardiology, a Fellow of the Faculty of Pharmaceutical Medicine and a Member of the Royal College of Surgeons of England.

Our Pipeline

We maximize the impact of genetic innovation to develop transformative therapies.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

View Now Our Pipeline